Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary

Health and Quality of Life Outcomes

Volumn 6, Issue , 2008, Pages

  Jermendy, György ^a   Erdesz, Diana ^b   Nagy, Laszlo ^b   Yin, Don ^c   Phatak, Hemant ^c   Karve, Sudeep ^d   Engel, Samuel ^c   Balkrishnan, Rajesh ^d  

^a BAJCSY ZSILINSZKY HOSPITAL   (Hungary)

^b Merck Sharpe and Dohme   (Hungary)

^c MERCK RESEARCH LABORATORIES   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DISEASE DURATION; DRUG TREATMENT FAILURE; FEMALE; GLYCEMIC CONTROL; HUMAN; HUNGARY; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; SELF REPORT; TREATMENT DURATION; AGED; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG EFFECT; EVALUATION; MIDDLE AGED; PATHOPHYSIOLOGY; SICKNESS IMPACT PROFILE; STATISTICS; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HUNGARY; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 57749206830     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-6-88     Document Type: Article

References (26)

1. Estimated prevalence of diabetes by country, 2003 and 2025, Europe International Diabetes Federation (2003) 2007 Ref Type: Electronic Citation
2. Doro P Benko R Kosik E Matuz M Toth K Soos G Utilization of oral antihyperglycemic drugs over a 7-year period (1998-2004) in a Hungarian population and adherence to drug therapy Eur J Clin Pharmacol 2005, 61:893-897 10.1007/s00228-005-0031-9 16328320
3. Roglic G Unwin N Bennett PH Mathers C Tuomilehto J Nag S Connolly V King H The burden of mortality attributable to diabetes: Realistic estimates for the year 2000 Diabetes Care 2005, 28:2130-2135 10.2337/ diacare.28.9.2130 16123478
4. Global Guideline for Type 2 Diabetes. INTERNATIONAL DIABETES FEDERATION, 2005 2005 Ref Type: Electronic Citation
5. Nathan DM Buse JB Davidson MB Heine RJ Holman RR Sherwin R Zinman B Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2006, 29:1963-1972 10.2337/dc06-9912 16873813
6. Nathan DM Buse JB Davidson MB Heine RJ Holman RR Sherwin R Zinman B Professional Practice Committee, American Diabetes Association; European Association for the Study of Diabetes. Management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 2006, 49:1711-1721 10.1007/s00125-006-0316-2 16802130
7. Davis S Alonso MD Hypoglycemia as a barrier to glycemic control J Diabetes Complications 2004, 18:60-68 10.1016/S1056-8727(03)00058-8 15019602
8. Shaw KM Overcoming the hurdles to achieving glycemic control Metabolism 2006, 55:S6-S9 10.1016/j.metabol.2006.02.001 16631808
9. Diagnosis and classification of diabetes mellitus Diabetes Care 2005, 28(Suppl 1):S37-42 15618111
10. Holmes J McGill S Kind P Bottomley J Gillam S Murphy M Health-related quality of life in type 2 diabetes (TARDIS-2) Value Health 2000, 3(Suppl 1):47-51 10.1046/j.1524-4733.2000.36028.x 16464209
11. Atkinson MJ Sinha A Hass SL Colman SS Kumar RN Brod M Rowland CR Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease Health Qual Life Outcomes 2004, 2:12 398419 14987333 10.1186/1477-7525-2-12
12. Grant RW Cagliero E Murphy-Sheehy P Singer DE Nathan DM Meigs JB Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes Am J Med 2002, 112:603-609 10.1016/S0002-9343(02)01103-8 12034408
13. Cook MN Girman CJ Stein PP Alexander CM Holman RR Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes Diabetes Care 2005, 28:995-1000 10.2337/diacare.28.5.995 15855556
14. Lawrence DB Ragucci KR Long LB Parris BS Helfer LA Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program J Manag Care Pharm 2006, 12:466-471 16925454
15. Rhee MK Slocum W Ziemer DC Culler SD Cook CB El-Kebbi IM Gallina DL Barnes C Phillips LS Patient adherence improves glycemic control Diabetes Educ 2005, 31:240-250 10.1177/0145721705274927 15797853
16. Bonora E Antidiabetic medications in overweight/obese patients with type 2 diabetes: Drawbacks of current drugs and potential advantages of incretin-based treatment on body weight Int J Clin Pract Suppl 2007:19-28 10.1111/j.1742-1241.2007.01441.x 17593274
17. Purnell JQ Weyer C Weight effect of current and experimental drugs for diabetes mellitus: From promotion to alleviation of obesity Treat Endocrinol 2003, 2:33-47 10.2165/00024677-200302010-00004 15871553
18. Currie CJ Morgan CL Poole CD Sharplin P Lammert M McEwan P Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes Curr Med Res Opin 2006, 22:1523-1534 10.1185/ 030079906X115757 16870077
19. Davis RE Morrissey M Peters JR Wittrup-Jensen K Kennedy-Martin T Currie CJ Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes Curr Med Res Opin 2005, 21:1477-1483 10.1185/ 030079905X61929 16197667
20. Lundkvist J Berne C Bolinder B Jonsson L The economic and quality of life impact of hypoglycemia Eur J Health Econ 2005, 6:197-202 10.1007/ s10198-005-0276-3 15761775
21. Stratton IM Adler AI Neil HA Matthews DR Manley SE Cull CA Hadden D Turner RC Holman RR Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study BMJ 2000, 321:405-412 27454 10938048 10.1136/ bmj.321.7258.405
22. Hermansen K Mortensen LS Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus Drug Saf 2007, 30:1127-1142 18035865
23. Barnett A Allsworth J Jameson K Mann R A review of the effects of antihyperglycaemic agents on body weight: The potential of incretin targeted therapies Curr Med Res Opin 2007, 23:1493-1507 10.1185/ 030079907X199691 17559747
24. Strowig SM Raskin P Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus Diabetes Obes Metab 2005, 7:633-641 10.1111/j.1463-1326.2004.00440.x 16219007
25. Phatak HM Yin DD Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA(1c): A meta-analysis of published randomized clinical trials Curr Med Res Opin 2006, 22:2267-2278 10.1185/ 030079906X148328 17076987
26. Centers for Disease Control and Prevention National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005 Atlanta, GA. U.S.Department ofHealth and Human Services, Centers for Disease Control and Prevention, 2005 2006 Ref Type: Electronic Citation